Environment
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
StateNew HampshireIntroduced
HB 1292: expanding the right to try act to include certain qualifying severe illness and permitting certain regenerative stem cell therapies under the act.
Erica Layon
HB 1292 status: Introduced — Executive Session: 09/30/2026 10:00 am GP 230 (updated Sep 4, 2026).
Source
LegiScan
Confidence
High
Analysis basis
LegiScan full bill text
01
What this bill does
Official summary alongside an AI-generated read on where it stands and why.
Overall Score
53OUT OF 100
Score:53/100 civic fit
Risk:Moderate Risk
Impact:Moderate Impact 60/100
Constitutionality70%
Bipartisan65%
Public opinion50%
Bill summary
What changes
Extends existing 'Right to Try' laws to include chronic and debilitating illnesses and authorizes specific regenerative stem cell therapies.
Who is affected
Patients with qualifying severe illnesses, physicians practicing in orthopedics, wound care, or pain management, and medical facilities.
Requirements and enforcement
Requires facility accreditation for stem cell storage, specific informed consent disclosures, advertising notices, and prohibition on fetal/embryonic tissue derived from abortions.
Costs and funding
The fiscal note states expenditures are indeterminate; costs for treatment are private and not covered by state mandate for insurers.
When it takes effect
Effective January 1, 2027.
Potential benefits
Expands therapeutic options for patients with chronic conditions and fosters medical innovation in regenerative medicine.
Risks and tradeoffs
Potential for patient harm from unapproved therapies, lack of insurance coverage, and potential for conflict with federal FDA regulations.
What is still unknown
The long-term safety profile of the permitted regenerative therapies remains unknown.
02
Impact analysis
✦ AI analysisModeled effects across six domains, estimated from bill text and comparable legislation.
Economy
Mixed / Neutral
50%
Benefits
- Permits medical facilities to offer new services
- Reduces regulatory barriers for regenerative medicine startups
- Allows payment arrangements between manufacturers and patients
Risks
- No state mandate for health insurer coverage
- Potential high out-of-pocket costs for patients
- Indeterminable state/local fiscal impact on judicial system
Society
Positive outlook
60%
Benefits
- Expands treatment access for chronic/debilitating illnesses
- Enhances patient autonomy in medical decision-making
- Provides clear guidelines for informed patient consent
Risks
- Risk of patient exploitation by unproven therapies
- Potential for disparate access based on financial status
- Reliance on patient's own financial resources
Technology Industry
No direct effect
Neutral — no direct effect identified.
Benefits
- No material direct effect identified.
Risks
- No material direct effect identified.
Civic Accountability
Mixed / Neutral
50%
Benefits
- Requires standardized accreditation for stem cell facilities
- Mandates clear physician disclosures in advertising
- Provides injunctive relief for statutory violations
Risks
- Risk of creating an end-run around federal FDA oversight
- Complexity of enforcing accreditation standards at state level
- Potential for regulatory ambiguity between state and federal law
Public Health & Safety
Mixed / Neutral
50%
Benefits
- Allows access to alternative therapies for severe cases
- Prohibits use of fetal/embryonic tissue from abortions
- Requires verification of cell viability post-thaw
Risks
- Permits medical use of FDA-unapproved therapies
- Possible side effects from untested or experimental procedures
- Inadequate long-term longitudinal data on safety outcomes
03
How trustworthy & consequential it is
Sourcing already shown above, this is what the analysis found worth flagging.
Source
LegiScan
Official bill text or data from LegiScan.
Confidence
High
Information is complete and verified.
Analysis basis
LegiScan full bill text
Source used for this bill's analysis.
Source note
Patients may undergo unproven therapies without federal safety assurance
Analysis scope
Fiscal impact is indeterminate and relies on judicial enforcement volume
04
Where it stands
Official record- IntroducedCurrent
- CommitteeUpcoming
- Chamber votesUpcoming
- Final agreementUpcoming
- GovernorUpcoming
- EnactedUpcoming
05
How it affects your district
✦ Personalized
Set your location
Add your district to see how this bill may affect your community and who to contact.
Your Representatives
Your representatives appear here once you add your location.
06
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.